Insulet Corporation
Insulet Reports Strong Q1 2026 Financial Results and Raises Full-Year Revenue Guidance
Summary
Insulet Corporation announced its financial results for the first quarter of 2026, reporting a 33.9% increase in revenue to $761.7 million, driven by a 36.9% rise in Omnipod revenue. The company also raised its full-year total company revenue guidance to 20%-22% growth in constant currency. Net income increased to $91.1 million, or $1.30 per diluted share, compared to $35.4 million, or $0.50 per diluted share, in the prior year. The company also provided guidance for the second quarter and full year 2026, with expectations of continued growth in both U.S. and international Omnipod sales.
Profitelligence Alerts
Get alerts for PODD
Be first to know when Insulet Corporation files with the SEC.
Filing Categories
Advertisement
About Insulet Corporation
Insulet Corporation is a prominent healthcare company specializing in medical devices, with a key focus on diabetes management. Its flagship product, the Omnipod Insulin Management System, is an innovative, tubeless insulin pump that offers users freedom and flexibility, addressing the lifelong needs of individuals with diabetes. The system is acclaimed for its discreet, water-resistant pods, which deliver continuous insulin delivery without the constraints of traditional insulin pumps. Insulet Corporation plays a crucial role in the medical technology industry by enhancing patient experiences and outcomes. Headquartered in Acton, Massachusetts, Insulet Corporation continues to pioneer advancements in insulin delivery solutions, directly impacting healthcare providers and improving the quality of life for diabetes patients globally. Its market significance is underscored by its commitment to innovation and accessibility, bridging the gap between technology and patient-centric care in the rapidly evolving healthcare sector.
Official SEC Documents
Advertisement